Status Epilepticus in Pediatric patients Severity Score (STEPSS) as an outcome predictor in children

Background Status epilepticus (SE) is a neurological emergency, with short-term mortality ranging from 0.9 to 3.6 in children. The disease burden of SE includes morbidity, treatment costs, and mortality. Various scoring tools for predicting outcomes in adult SE cases have been widely studied, but th...

Full description

Bibliographic Details
Main Authors: Iswarajati, Niken, Kumara, Intan Fatah, Triono, Agung
Format: Article
Language:English
Published: Indonesian Pediatric Society Publishing House 2022
Subjects:
Online Access:https://repository.ugm.ac.id/283309/1/40.pdf
Description
Summary:Background Status epilepticus (SE) is a neurological emergency, with short-term mortality ranging from 0.9 to 3.6 in children. The disease burden of SE includes morbidity, treatment costs, and mortality. Various scoring tools for predicting outcomes in adult SE cases have been widely studied, but there are few tools for predicting outcomes in children with SE. Objective To evaluate the usefulness of Status Epilepticus in Pediatric patients Severity Score (STEPSS), a clinical score for predicting functional outcomes and mortality in pediatric patients with status epilepticus, as well as to identify characteristics of SE patients. Methods This retrospective cohort study included 88 pediatric patients with status epilepticus aged >1 month to ≤18 years by consecutive sampling, who were treated at Dr. Sardjito Hospital, Yogyakarta. All subjects underwent assessment by STEPSS, which were compared to functional outcomes assessed by Pediatric Overall Performance Capacity (POPC) score and mortality. Results STEPSS > 3 was significantly correlated with poor functional outcomes (OR 2.85; 95CI 1.04 to 7.87; P=0.043), but was not significantly correlated with mortality outcome in children with SE (P=0.411). Conclusion Status Epilepticus in Pediatric patients Severity Score (STEPSS) with cut-off >3 can be used as a predictor of poor functional outcomes in pediatric patients with SE aged >1 month to ≤18 years, but cannot be used as a predictor of mortality. © 2022, Indonesian Pediatric Society Publishing House. All rights reserved.